Why the study?
Does amlodipine reduce blood pressure more effectively than verapamil or placebo in patients with mild to moderate essential hypertension?
Does amlodipine reduce blood pressure more effectively than verapamil or placebo in patients with mild to moderate essential hypertension?
Amlodipine once daily is a more effective antihypertensive agent than verapamil twice daily for mild to moderate hypertension, with a sustained 24-hour effect and low incidence of adverse effects.
Answers are grounded in this paper and cite their sources.
Amlodipine achieves greater BP reduction than verapamil in mild-moderate hypertension; reinforces once-daily dihydropyridine preference with sustained effect.
Summary: One hundred sixty patients with mild to moderate essential hypertension entered this double-blind parallel group comparison of amlodipine, verapamil, and placebo. Sixteen centers from the United Kingdom and Norway participated in this multicenter study, Administration of amlodipine (2.5 mg with adjustment to 5.0 mg and to 10.0 mg o.d.) or verapamil (80 mg b.i.d. titrating to 160 mg b.i.d.) for 8 weeks to patients with mild to moderate hypertension was associated with clinically important and statistically significant decreases in both supine and standing blood pressures. After 8 weeks of double-blind therapy, the mean (amlodipine-placebo) difference in the falls from baseline in blood pressures measured 24 h postdose were -11.9/-7.0 mm Hg (supine) and -11.4/-6.3 mm Hg (standing). The corresponding figures were-7.7/-4.6 mm Hg and -8.3/-4.0 mm Hg for verapamil (12 h postdose). Mean reductions from baseline of the amlodipine group exceeded those of the verapamil group by 2-4 mm Hg for all pressure measurements, and this difference was statistically significant for diastolic blood pressures. Responder rates were 72, 48, and 33% for amlodipine, verapamil, and placebo, respectively. Mean doses at 8 weeks were 9.1 mg (amlodipine) and 296 mg (verapamil). There were no significant changes in pulse rate. Both active drugs maintained their antihypertensive effect through the day (0-12 h postdose) with amlodipine showing a sustained 24-h effect. Twentytwo patients in the amlodipine, 19 in the verapamil, and 14 in the placebo groups had side effects possibly related to treatment. The most common side effect associated with amlodipine was peripheral edema (12 occurrences), necessitating withdrawal of two patients from the study. Headache was reported by five verapamil-treated and four placebo-treated patients; two verapamil-treated patients and one placebo-treated patient were withdrawn. Moderate elevations of liver function tests were possibly drug related (one patient amlodipine, three verapamil). Other laboratory test abnormalities were of little clinical significance. Amlodipine once daily appears to be a more effective antihypertensive agent than verapamil twice daily and is associated with a low incidence of adverse effects.
No takes yet. Share an insight, caveat, or question.
Lorimer et al. (1988) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: